Bristol Myers Squibb’s Opdivo (nivolumab) plus Yervoy (ipilimumab) combination has demonstrated ‘durable improvement in survival’, according to new long-term data from a Phase III trial.
Archive | Of Interest
BMS’ Opdivo/Yervoy improves long-term survival for melanoma patients
Posted in Melanoma News, Health Professionals, Of Interest
Screening and Identification of Key Biomarkers in Melanoma
Malignant melanoma is uncommon worldwide, accounting for only ?1% of all malignant tumors.
Posted in Melanoma News, Health Professionals, Of Interest
Vidutolimod/Nivolumab Under Evaluation in PD-1-Refractory Advanced Melanoma
The safety and efficacy of the combination of vidutolimod (CMP-001) and nivolumab (Opdivo) is currently under investigation in patients with PD-1–refractory advanced melanoma, as part of the ongoing phase 2 CMP-001-010 trial (NCT04698187).1
Posted in Melanoma News, Health Professionals, Of Interest
Australian researchers lead world in successful trial of new cancer treatment
In a breakthrough which could extend to the treatment of other cancers, a new immune checkpoint inhibitor has proven effective in helping save the lives of advanced melanoma patients.
Posted in Melanoma News, Health Professionals, Of Interest
